The Final Maturation State of β-actin Involves N-terminal Acetylation by NAA80, not N-terminal Arginylation by ATE1.


Journal

Journal of molecular biology
ISSN: 1089-8638
Titre abrégé: J Mol Biol
Pays: Netherlands
ID NLM: 2985088R

Informations de publication

Date de publication:
30 01 2022
Historique:
received: 14 11 2021
revised: 03 12 2021
accepted: 04 12 2021
pubmed: 14 12 2021
medline: 5 2 2022
entrez: 13 12 2021
Statut: ppublish

Résumé

Actin is a hallmark protein of the cytoskeleton in eukaryotic cells, affecting a range of cellular functions. Actin dynamics is regulated through a myriad of actin-binding proteins and post-translational modifications. The mammalian actin family consists of six different isoforms, which vary slightly in their N-terminal (Nt) sequences. During and after synthesis, actins undergo an intricate Nt-processing that yields mature actin isoforms. The ubiquitously expressed cytoplasmic β-actin is Nt-acetylated by N-alpha acetyltransferase 80 (NAA80) yielding the Nt-sequence Ac-DDDI-. In addition, β-actin was also reported to be Nt-arginylated by arginyltransferase 1 (ATE1) after further peptidase-mediated processing, yielding RDDI-. To characterize in detail the Nt-processing of actin, we used state-of-the-art proteomics. To estimate the relative cellular levels of Nt-modified proteoforms of actin, we employed NAA80-lacking cells, in which actin was not Nt-acetylated. We found that targeted proteomics is superior to a commercially available antibody previously used to analyze Nt-arginylation of β-actin. Significantly, despite the use of sensitive mass spectrometry-based techniques, we could not confirm the existence of the previously claimed Nt-arginylated β-actin (RDDI-) in either wildtype or NAA80-lacking cells. A very minor level of Nt-arginylation of the initially cleaved β-actin (DDDI-) could be identified, but only in NAA80-lacking cells, not in wildtype cells. We also identified small fractions of cleaved and unmodified β-actin (DDI-) as well as cleaved and Nt-acetylated β-actin (Ac-DDI-). In sum, we show that the multi-step Nt-maturation of β-actin is terminated by NAA80, which Nt-acetylates the exposed Nt-Asp residues, in the virtual absence of previously claimed Nt-arginylation.

Identifiants

pubmed: 34896361
pii: S0022-2836(21)00634-3
doi: 10.1016/j.jmb.2021.167397
pmc: PMC7613935
mid: EMS158168
pii:
doi:

Substances chimiques

Actins 0
Protein Isoforms 0
Acetyltransferases EC 2.3.1.-
NAA80 protein, human EC 2.3.1.-
ATE1 protein, human EC 2.3.2.-
Aminoacyltransferases EC 2.3.2.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

167397

Subventions

Organisme : European Research Council
ID : 772039
Pays : International

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Sci Rep. 2018 Nov 1;8(1):16177
pubmed: 30385798
Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):E2716-E2724
pubmed: 29507222
FEBS J. 2018 Sep;285(17):3299-3316
pubmed: 30028079
Brain Commun. 2021 Oct 26;3(4):fcab256
pubmed: 34805998
Commun Integr Biol. 2018 Oct 21;11(4):e1526572
pubmed: 30534344
Anal Chem. 2013 Nov 19;85(22):11054-60
pubmed: 24134513
Nat Cell Biol. 2015 Jul;17(7):917-29
pubmed: 26075355
Biochem Biophys Res Commun. 2000 Feb 5;268(1):14-9
pubmed: 10652204
Science. 2009 Nov 27;326(5957):1208-12
pubmed: 19965462
J Mol Biol. 2003 Jan 24;325(4):595-622
pubmed: 12507466
Trends Biochem Sci. 2019 Jun;44(6):502-516
pubmed: 30611609
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):4399-4404
pubmed: 29581253
Cell Mol Life Sci. 2021 Apr;78(7):3725-3741
pubmed: 33687501
Sci Adv. 2020 Apr 08;6(15):eaay8793
pubmed: 32284999
Mol Biol Cell. 2010 Apr 15;21(8):1350-61
pubmed: 20181827
Protein Sci. 2011 Aug;20(8):1298-345
pubmed: 21633985
J Mol Biol. 1978 Dec 25;126(4):783-802
pubmed: 745245
ACS Omega. 2020 Mar 17;5(12):6754-6762
pubmed: 32258910
Development. 2008 Dec;135(23):3881-9
pubmed: 18948421
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):358-366
pubmed: 30622213
Mol Biol Cell. 2019 Feb 15;30(4):453-466
pubmed: 30586322
Science. 2006 Jul 14;313(5784):192-6
pubmed: 16794040
Sci Rep. 2019 Nov 13;9(1):16669
pubmed: 31723207
Dev Biol. 2017 Oct 1;430(1):41-51
pubmed: 28844905
J Biol Chem. 1983 Mar 25;258(6):3961-6
pubmed: 6833238
Science. 2010 Sep 17;329(5998):1534-7
pubmed: 20847274
J Biol Chem. 1981 Dec 25;256(24):13226-9
pubmed: 7309760
Biol Open. 2020 Nov 12;9(11):
pubmed: 33184093
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):4405-4410
pubmed: 29581307
Exp Mol Med. 2018 Jul 27;50(7):1-13
pubmed: 30054468
Proteomics. 2015 Jul;15(14):2385-401
pubmed: 25914051
Mol Cell Proteomics. 2012 May;11(5):202-14
pubmed: 22454539
PLoS Biol. 2007 Oct;5(10):e258
pubmed: 17896865
J Biol Chem. 1992 Oct 5;267(28):20217-24
pubmed: 1400339
Cold Spring Harb Perspect Biol. 2016 Aug 01;8(8):
pubmed: 26988969
Proteomics. 2012 Apr;12(8):1122-33
pubmed: 22577013
Traffic. 2018 Apr;19(4):263-272
pubmed: 29384244
Cell Death Discov. 2016 Oct 03;2:16074
pubmed: 27752365
J Biol Chem. 2014 Dec 19;289(51):35376-87
pubmed: 25381249
J Biol Chem. 2012 Jul 6;287(28):24043-52
pubmed: 22577142
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12449-54
pubmed: 22814378
J Biol Chem. 2020 Dec 4;295(49):16713-16731
pubmed: 32978259
Science. 2002 Jul 5;297(5578):96-9
pubmed: 12098698
Biochem J. 2010 Jul 1;429(1):63-72
pubmed: 20423325
J Neurochem. 2016 Aug;138(4):506-17
pubmed: 27318192
Methods Mol Biol. 2017;1574:9-15
pubmed: 28315240
Neurochem Res. 2006 Mar;31(3):401-9
pubmed: 16733816

Auteurs

Adrian Drazic (A)

Department of Biomedicine, University of Bergen, N-5020 Bergen, Norway.

Evy Timmerman (E)

VIB-UGent Center for Medical Biotechnology, B-9000 Ghent, Belgium; VIB Proteomics Core, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent, Belgium.

Ulrike Kajan (U)

Department of Biomedicine, University of Bergen, N-5020 Bergen, Norway.

Michaël Marie (M)

Department of Biomedicine, University of Bergen, N-5020 Bergen, Norway.

Sylvia Varland (S)

Department of Biomedicine, University of Bergen, N-5020 Bergen, Norway; Department of Biological Sciences, University of Bergen, N-5020 Bergen, Norway.

Francis Impens (F)

VIB-UGent Center for Medical Biotechnology, B-9000 Ghent, Belgium; VIB Proteomics Core, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent, Belgium.

Kris Gevaert (K)

VIB-UGent Center for Medical Biotechnology, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000 Ghent, Belgium.

Thomas Arnesen (T)

Department of Biomedicine, University of Bergen, N-5020 Bergen, Norway; Department of Biological Sciences, University of Bergen, N-5020 Bergen, Norway; Department of Surgery, Haukeland University Hospital, N-5021 Bergen, Norway. Electronic address: thomas.arnesen@uib.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH